OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Erickson on PARP Inhibitor Maintenance Therapy in BRCA-Mutated Ovarian Cancer

November 24th 2021

Britt Erickson, MD, discusses the benefit of PARP inhibitor maintenance therapy in patients with BRCA-mutated ovarian cancer.

Dr. Saif on Recommendations for Germline Testing in Pancreatic Cancer

November 23rd 2021

Wasif M. Saif, MD, MBBS, discusses recommendations for germline testing in patients with pancreatic cancer.

Dr. Vasan on Future Research Directions for Approved Agents in HER2+ Breast Cancer

November 23rd 2021

Neil Vasan, MD, PhD, discusses future research directions for approved agents used in the treatment of patients with HER2-positive breast cancer.

Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma

November 23rd 2021

Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.

Dr. Reiss Binder on Initial Results of a Phase 1 Study of CT-0508 in HER2+ Solid Tumors

November 23rd 2021

Kim A. Reiss Binder, MD, discusses the initial results of a phase 1 trial, which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors.

Dr. Iqbal on the Emergence of Checkpoint Inhibitors in Upper GI Cancers

November 23rd 2021

Syma Iqbal, MD, discusses the emergence of checkpoint inhibitors in upper gastrointestinal cancers.

Dr. Rosko on Disparities Within Clinical Trials in Multiple Myeloma

November 23rd 2021

Ashley E. Rosko, MD, discusses disparities within clinical trials in multiple myeloma.

Dr. Vaishampayan on the Future Directions for Second-Line Treatment in Urothelial Cancer

November 23rd 2021

Ulka Nitin Vaishampayan, MBBS, discusses future directions for second-line treatment in urothelial cancer.

Dr. Evens on Key Highlights from the RWJ Annual Clinical Practice and Research Summit

November 23rd 2021

Andrew M. Evens, DO, MSc, discusses highlights from the 2021 RWJ Annual Clinical and Practice Research Summit.

Dr. Hinrichs on Unmet Needs with Cellular Therapy in Metastatic Epithelial Cancer

November 23rd 2021

Christian S. Hinrichs, MD, discusses unmet needs with cellular therapies in metastatic epithelial cancer.

Dr. Malhotra on Challenges with Precision Medicine in Advanced Solid Tumors

November 23rd 2021

Jyoti Malhotra, MD, MPH, discusses challenges with precision medicine in advanced solid tumors.

Dr. Bupathi on Considerations for Second-Line Sequencing in RCC

November 23rd 2021

Manojkumar Bupathi, MD, MS, discusses considerations for second-line treatment sequencing in clear cell renal cell carcinoma.

Dr. Palmbos on Remaining Questions in Metastatic Urothelial Carcinoma

November 22nd 2021

Phillip L. Palmbos, MD, PhD, discusses remaining questions in metastatic urothelial carcinoma.

Dr. Lee on Defining Smoldering Multiple Myeloma

November 22nd 2021

Sarah S. Lee, MD, discusses definition criteria for smoldering multiple myeloma.

Dr. Galsky on Developments in SOC Metastatic Urothelial Cancer Treatment

November 22nd 2021

Matthew Galsky, MD, discusses key developments in the standard-of-care treatment of patients with metastatic or advanced urothelial cancer.

Dr. Cohen on the Importance of Obtaining an Adequate Tissue Sample in GI Malignancies

November 22nd 2021

Steven J. Cohen, MD, discusses the importance of obtaining an adequate tissue sample for molecular testing in gastrointestinal cancers.

Dr. Ganesan on Leveraging Precision Medicine to Improve Cancer Care

November 22nd 2021

Shridar Ganesan, MD, PhD, discusses improvements in precision medicine and the need to enroll patients with different molecular subtypes into specifically designed clinical trials.

Dr. Hochster on Treatment Considerations for HER2+ Gastric Cancer

November 22nd 2021

Howard S. Hochster, MD, FACP, discusses treatment considerations for patients with HER2-positive gastric cancer.

Dr. Wilky on the Diagnosis and Management of Desmoid Tumors

November 19th 2021

Breelyn Wilky, MD, discusses the diagnosis and management of desmoid tumors.

Dr. Falkson on Opportunities for De-Escalating Therapy in HER2+ Breast Cancer

November 19th 2021

Carla Falkson, MBChB, MMed, MD, discusses opportunities for de-escalating therapy in patients with HER2-positive breast cancer.